{
  "paper_id": "PMC10425528",
  "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425528/",
  "figures": {
    "figure_1": {
      "figure_number": "Figure 1",
      "title": "Fig. 1.",
      "caption": "HR positive/HER2-negative early breast cancer algorithm. AI: aromatase inhibitors; BCS: breast conservation; CT: chemotherapy; ET: endocrine therapy; N: axillar node; OFS: ovarian function suppression; y: years; +:  positive; -: negative. *Consider in premenopausal patients with luminal A-like tumors and no indication for chemotherapy, who are not candidates for optimal surgery, OFS plus an aromatase inhibitor can be considered",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/021d/10425528/d70025d101d6/12094_2023_3215_Fig1_HTML.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/021d/10425528/d70025d101d6/12094_2023_3215_Fig1_HTML.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/021d/10425528/d70025d101d6/12094_2023_3215_Fig1_HTML.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/021d/10425528/d70025d101d6/12094_2023_3215_Fig1_HTML.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "Fig1",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/021d/10425528/d70025d101d6/12094_2023_3215_Fig1_HTML.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC10425528/images/figure_1.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/021d/10425528/d70025d101d6/12094_2023_3215_Fig1_HTML.jpg"
    },
    "figure_2": {
      "figure_number": "Figure 2",
      "title": "Fig. 2.",
      "caption": "HER2-positive early breast cancer algorithm. CT: chemotherapy. pCR: pathologic complete response. (1) This treatment is still awaiting financial approval from the health authorities in Spain",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/021d/10425528/7f9c71ed07c3/12094_2023_3215_Fig2_HTML.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/021d/10425528/7f9c71ed07c3/12094_2023_3215_Fig2_HTML.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/021d/10425528/7f9c71ed07c3/12094_2023_3215_Fig2_HTML.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/021d/10425528/7f9c71ed07c3/12094_2023_3215_Fig2_HTML.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "Fig2",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/021d/10425528/7f9c71ed07c3/12094_2023_3215_Fig2_HTML.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC10425528/images/figure_2.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/021d/10425528/7f9c71ed07c3/12094_2023_3215_Fig2_HTML.jpg"
    },
    "figure_3": {
      "figure_number": "Figure 3",
      "title": "Fig. 3.",
      "caption": "Triple negative early breast cancer algorithm. CT: chemotherapy. pCR: pathologic complete response",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/021d/10425528/e97b20a634cc/12094_2023_3215_Fig3_HTML.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/021d/10425528/e97b20a634cc/12094_2023_3215_Fig3_HTML.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/021d/10425528/e97b20a634cc/12094_2023_3215_Fig3_HTML.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/021d/10425528/e97b20a634cc/12094_2023_3215_Fig3_HTML.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "Fig3",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/021d/10425528/e97b20a634cc/12094_2023_3215_Fig3_HTML.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC10425528/images/figure_3.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/021d/10425528/e97b20a634cc/12094_2023_3215_Fig3_HTML.jpg"
    }
  },
  "claims": [
    {
      "sentence": "Adjuvant systemic therapy is best started without undue delays, as data reveal an important decrease in efficacy when it is administered > 12 weeks after surgery (I, A) [54] (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "This dual HER2 blockade efficacy has been endorsed by the latest analysis of CLEOPATRA study confirming OS benefit in the advanced setting [91] (I, A) (Fig. 2)\nEstablished NAC regimens are either an anthracycline-taxane sequence plus P + T or docetaxel-carboplatin plus dual HER2 blockade, for a minimum of 9 weeks of taxane + antiHER2 therapy.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Since systemic therapy should be considered in all stage I tumors (except in those ≤ 5 mm, with an excellent prognosis without CT) [106], administration of systemic neoadjuvant therapy could yield locoregional benefits and offer response information (Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "MJVL, SAN, AS, LGC, CME, TMM have nothing to disclose.Ethical approval\nThe current study has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.Informed consent\nNo informed consent was required for this type of article.Footnotes\n\nThe original online version of this article was revised to correct Figure 3.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Adjuvant systemic therapy is best started without undue delays, as data reveal an important decrease in efficacy when it is administered > 12 weeks after surgery (I, A) [54] (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "This dual HER2 blockade efficacy has been endorsed by the latest analysis of CLEOPATRA study confirming OS benefit in the advanced setting [91] (I, A) (Fig. 2)\nEstablished NAC regimens are either an anthracycline-taxane sequence plus P + T or docetaxel-carboplatin plus dual HER2 blockade, for a minimum of 9 weeks of taxane + antiHER2 therapy.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Since systemic therapy should be considered in all stage I tumors (except in those ≤ 5 mm, with an excellent prognosis without CT) [106], administration of systemic neoadjuvant therapy could yield locoregional benefits and offer response information (Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "MJVL, SAN, AS, LGC, CME, TMM have nothing to disclose.Ethical approval\nThe current study has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.Informed consent\nNo informed consent was required for this type of article.Footnotes\n\nThe original online version of this article was revised to correct Figure 3.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Adjuvant systemic therapy is best started without undue delays, as data reveal an important decrease in efficacy when it is administered > 12 weeks after surgery (I, A) [54] (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "This dual HER2 blockade efficacy has been endorsed by the latest analysis of CLEOPATRA study confirming OS benefit in the advanced setting [91] (I, A) (Fig. 2)\nEstablished NAC regimens are either an anthracycline-taxane sequence plus P + T or docetaxel-carboplatin plus dual HER2 blockade, for a minimum of 9 weeks of taxane + antiHER2 therapy.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Since systemic therapy should be considered in all stage I tumors (except in those ≤ 5 mm, with an excellent prognosis without CT) [106], administration of systemic neoadjuvant therapy could yield locoregional benefits and offer response information (Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "MJVL, SAN, AS, LGC, CME, TMM have nothing to disclose.Ethical approval\nThe current study has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.Informed consent\nNo informed consent was required for this type of article.Footnotes\n\nThe original online version of this article was revised to correct Figure 3.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Adjuvant systemic therapy is best started without undue delays, as data reveal an important decrease in efficacy when it is administered > 12 weeks after surgery (I, A) [54] (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "This dual HER2 blockade efficacy has been endorsed by the latest analysis of CLEOPATRA study confirming OS benefit in the advanced setting [91] (I, A) (Fig. 2)\nEstablished NAC regimens are either an anthracycline-taxane sequence plus P + T or docetaxel-carboplatin plus dual HER2 blockade, for a minimum of 9 weeks of taxane + antiHER2 therapy.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Since systemic therapy should be considered in all stage I tumors (except in those ≤ 5 mm, with an excellent prognosis without CT) [106], administration of systemic neoadjuvant therapy could yield locoregional benefits and offer response information (Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "MJVL, SAN, AS, LGC, CME, TMM have nothing to disclose.Ethical approval\nThe current study has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.Informed consent\nNo informed consent was required for this type of article.Footnotes\n\nThe original online version of this article was revised to correct Figure 3.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Adjuvant systemic therapy is best started without undue delays, as data reveal an important decrease in efficacy when it is administered > 12 weeks after surgery (I, A) [54] (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "This dual HER2 blockade efficacy has been endorsed by the latest analysis of CLEOPATRA study confirming OS benefit in the advanced setting [91] (I, A) (Fig. 2)\nEstablished NAC regimens are either an anthracycline-taxane sequence plus P + T or docetaxel-carboplatin plus dual HER2 blockade, for a minimum of 9 weeks of taxane + antiHER2 therapy.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Since systemic therapy should be considered in all stage I tumors (except in those ≤ 5 mm, with an excellent prognosis without CT) [106], administration of systemic neoadjuvant therapy could yield locoregional benefits and offer response information (Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "MJVL, SAN, AS, LGC, CME, TMM have nothing to disclose.Ethical approval\nThe current study has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.Informed consent\nNo informed consent was required for this type of article.Footnotes\n\nThe original online version of this article was revised to correct Figure 3.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Adjuvant systemic therapy is best started without undue delays, as data reveal an important decrease in efficacy when it is administered > 12 weeks after surgery (I, A) [54] (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "This dual HER2 blockade efficacy has been endorsed by the latest analysis of CLEOPATRA study confirming OS benefit in the advanced setting [91] (I, A) (Fig. 2)\nEstablished NAC regimens are either an anthracycline-taxane sequence plus P + T or docetaxel-carboplatin plus dual HER2 blockade, for a minimum of 9 weeks of taxane + antiHER2 therapy.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Since systemic therapy should be considered in all stage I tumors (except in those ≤ 5 mm, with an excellent prognosis without CT) [106], administration of systemic neoadjuvant therapy could yield locoregional benefits and offer response information (Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "MJVL, SAN, AS, LGC, CME, TMM have nothing to disclose.Ethical approval\nThe current study has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.Informed consent\nNo informed consent was required for this type of article.Footnotes\n\nThe original online version of this article was revised to correct Figure 3.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Adjuvant systemic therapy is best started without undue delays, as data reveal an important decrease in efficacy when it is administered > 12 weeks after surgery (I, A) [54] (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "This dual HER2 blockade efficacy has been endorsed by the latest analysis of CLEOPATRA study confirming OS benefit in the advanced setting [91] (I, A) (Fig. 2)\nEstablished NAC regimens are either an anthracycline-taxane sequence plus P + T or docetaxel-carboplatin plus dual HER2 blockade, for a minimum of 9 weeks of taxane + antiHER2 therapy.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Since systemic therapy should be considered in all stage I tumors (except in those ≤ 5 mm, with an excellent prognosis without CT) [106], administration of systemic neoadjuvant therapy could yield locoregional benefits and offer response information (Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "MJVL, SAN, AS, LGC, CME, TMM have nothing to disclose.Ethical approval\nThe current study has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.Informed consent\nNo informed consent was required for this type of article.Footnotes\n\nThe original online version of this article was revised to correct Figure 3.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Adjuvant systemic therapy is best started without undue delays, as data reveal an important decrease in efficacy when it is administered > 12 weeks after surgery (I, A) [54] (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "This dual HER2 blockade efficacy has been endorsed by the latest analysis of CLEOPATRA study confirming OS benefit in the advanced setting [91] (I, A) (Fig. 2)\nEstablished NAC regimens are either an anthracycline-taxane sequence plus P + T or docetaxel-carboplatin plus dual HER2 blockade, for a minimum of 9 weeks of taxane + antiHER2 therapy.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Since systemic therapy should be considered in all stage I tumors (except in those ≤ 5 mm, with an excellent prognosis without CT) [106], administration of systemic neoadjuvant therapy could yield locoregional benefits and offer response information (Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "MJVL, SAN, AS, LGC, CME, TMM have nothing to disclose.Ethical approval\nThe current study has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.Informed consent\nNo informed consent was required for this type of article.Footnotes\n\nThe original online version of this article was revised to correct Figure 3.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Adjuvant systemic therapy is best started without undue delays, as data reveal an important decrease in efficacy when it is administered > 12 weeks after surgery (I, A) [54] (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Adjuvant systemic therapy is best started without undue delays, as data reveal an important decrease in efficacy when it is administered > 12 weeks after surgery (I, A) [54] (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Adjuvant systemic therapy is best started without undue delays, as data reveal an important decrease in efficacy when it is administered > 12 weeks after surgery (I, A) [54] (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "This dual HER2 blockade efficacy has been endorsed by the latest analysis of CLEOPATRA study confirming OS benefit in the advanced setting [91] (I, A) (Fig. 2)\nEstablished NAC regimens are either an anthracycline-taxane sequence plus P + T or docetaxel-carboplatin plus dual HER2 blockade, for a minimum of 9 weeks of taxane + antiHER2 therapy.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "This dual HER2 blockade efficacy has been endorsed by the latest analysis of CLEOPATRA study confirming OS benefit in the advanced setting [91] (I, A) (Fig. 2)\nEstablished NAC regimens are either an anthracycline-taxane sequence plus P + T or docetaxel-carboplatin plus dual HER2 blockade, for a minimum of 9 weeks of taxane + antiHER2 therapy.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "This dual HER2 blockade efficacy has been endorsed by the latest analysis of CLEOPATRA study confirming OS benefit in the advanced setting [91] (I, A) (Fig. 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Since systemic therapy should be considered in all stage I tumors (except in those ≤ 5 mm, with an excellent prognosis without CT) [106], administration of systemic neoadjuvant therapy could yield locoregional benefits and offer response information (Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Since systemic therapy should be considered in all stage I tumors (except in those ≤ 5 mm, with an excellent prognosis without CT) [106], administration of systemic neoadjuvant therapy could yield locoregional benefits and offer response information (Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Since systemic therapy should be considered in all stage I tumors (except in those ≤ 5 mm, with an excellent prognosis without CT) [106], administration of systemic neoadjuvant therapy could yield locoregional benefits and offer response information (Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Footnotes\n\nThe original online version of this article was revised to correct Figure 3.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The original online version of this article was revised to correct Figure 3.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The original online version of this article was revised to correct Figure 3.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The original online version of this article was revised to correct Figure 3.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    }
  ],
  "extraction_stats": {
    "figures_count": 3,
    "claims_count": 45,
    "images_downloaded": 3,
    "tables_filtered": 6
  }
}